ReportWire

Tag: Healthcare

  • How can primary health care help to close the epilepsy treatment gap? A journey through Andhra Pradesh, India

    How can primary health care help to close the epilepsy treatment gap? A journey through Andhra Pradesh, India

    [ad_1]

    Newswise — The role of primary health care in identifying, diagnosing, and treating people with epilepsy is increasingly important, particularly in view of the recent adoption of the Intersectoral Global Action Plan (IGAP) for Epilepsy and Neurological Disorders by the World Health Assembly.

    However, societal attitudes and stigma around epilepsy can be major barriers to improving care. Without at least a rough idea of how many people require diagnosis and treatment in a given area, it’s difficult to establish needs and gaps. In India, where many people keep epilepsy hidden even from care providers, mapping the current state of epilepsy care in a rural area of Andhra Pradesh was nearly an exercise in futility.

    A team of researchers visited two primary health care centers in Bhimaravam to assess care provided to people with epilepsy through the primary health care system. The visits were part of a coordinated clinical and research initiative called STOP-Epilepsy, which aims to improve epilepsy care in three districts in India:

    • Gauriganj in Uttar Pradesh
    • Bhimavaram in Andhra Pradesh
    • Nawanshahr in Punjab

    Bhimaravam, in coastal South India, has a population of about 225,000. Most people work in rice paddy cultivation or fish farming. The two health care centers—in Turputallu and Gollavanitippa—each provide service to approximately 50,000 people.

    “Reaching the centers took us a few hours,” said Gagandeep Singh, an epilepsy researcher from India. “This was largely because navigating the pot-holed road was quite a challenge.”

    Invisible epilepsy

    At each center, the team interacted with medical officers, pharmacists, nurse midwives and Accredited Social Health Activists (ASHA) workers.

    “We asked the medical officers how commonly they saw people with epilepsy during clinics,” said Singh. “At Turputallu, the doctor replied, ‘Not too many. I would see about 60 to 70 outpatients on any day and might see 1 or 2 people with epilepsy in a week.’”

    At Gollavanitippa, the pharmacist told the group that the pharmacy had 100 mg phenytoin tablets and injectable diazepam as anti-seizure medications.

    “When we asked about other epilepsy medicines, he replied, ‘Other epilepsy medicines are never prescribed, and so we never requisition them,’” said Singh. The small numbers of people with epilepsy in the clinics was the main reason cited for the limited availability of anti-seizure medications.

    ASHA workers in India: Community health at the village level

    Accredited Social Health Activist (ASHA) workers are female community members, usually between the ages of 25 and 40, who work mostly on a voluntary basis, though they do receive some financial compensation. They are trained by the Indian Ministry of Health and Family Welfare as part of the country’s National Health Mission, which aimed to establish one ASHA worker for every 1,000 residents

    ASHA workers must primarily be residents of the village or area they serve, and plan to remain living there for the foreseeable future. They promote healthy behaviors through education and prevention, assisting in health care access in villages and marginalized areas in Indian cities. They are a key factor in communication, awareness, and access to care in these areas.

    ASHA is not only an acronym; it means “hope” in Hindi.

    There are close to 1 million ASHA workers in India. In May 2022, ASHAs were one of six recipients of the World Health Organization’s Global Health Leaders Award.

     

    At Turputallu, the researchers asked ASHA workers how many people with epilepsy lived in the communities they served.

    “There was a long silence,” said Singh, “after which one of the ASHA workers said she was aware of one such case in her village.”

    When asked about problems that people with epilepsy could face, Singh mentioned that one worker believed people with epilepsy are usually fine but can have problems during “no-moon days.”

    The idea that seizures are somehow affected by the moon’s phases has been around for thousands of years. Romans referred to people with epilepsy as “lunaticus” (moonstruck) and believed the gods intervened during certain phases. Limited research suggests a possible negative association between seizure frequency and the fraction of the moon illuminated at night; however, other research suggests an opposite trend.

    At Gollavanitippa, ASHA workers at first said they knew of no one with epilepsy in their communities.

    “As the interpreter persisted, one said that she knew of a family in her village in which both brother and sister both had epilepsy,” said Singh. “The sister died prematurely, and the brother is seeking treatment for epilepsy from a private facility.  She also mentioned one woman who was on treatment and married off some time ago. But it seems that that the epilepsy was not declared during the marital negotiations, and there has been considerable discord between the natal and conjugal family on this account.”

    Marriage-related stigma

    Arranged marriages account for nearly 80% of all marriages in India and much of South Asia. Parents or elders in the family negotiate arranged marriages; potential marriage partners have little to no opportunity to meet or discuss issues.

    In India, epilepsy was legitimate grounds for divorce until 1999, when the Hindu Marriage Act was amended to remove it, largely due to the efforts of neurologists. Despite the legal gains, societal beliefs about epilepsy remain negative.

    “All ASHAs agreed that hiding epilepsy was fairly common among both genders, and this was done primarily by families to avoid ruining marital prospects,” Singh said. “Using indigenous medications or witchcraft was not common, however. People would like to visit a specialist, funds permitting.”

    Singh said another ASHA worker recalled a man who had epilepsy. She thought he might be visiting a private practitioner but was taking his medication irregularly because he could not afford a consistent supply.

    In regions of the world with few epilepsy specialists, the World Health Organization (WHO) encourages engagement of primary health care physicians and other health care providers in epilepsy care. However, said Singh, this visit suggested that at least in this Indian district, very few people with epilepsy visit primary health care centers. Even community health workers are aware of only a few people with epilepsy in the communities they serve.

    “Where then do people with epilepsy seek care?” asked Singh. “There could be alternative pathways of care, but in the case of Bhimaravam, there is no use of alternative medicines or traditional healers. Do they merely remain behind shadows?”

    Medication issues

    Despite the number of anti-seizure medications on the WHO and Indian lists of essential medicines, primary health care dispensaries have few of these medications available. And primary care providers in Bhimaravam appear to see few people with epilepsy.

    “Even if more people arrived at primary care centers for diagnosis and treatment of epilepsy, would care providers be able to manage their epilepsy effectively?” asked Singh.

    The trip to Bhimavaram emphasizes that there are multiple barriers to obtaining effective care, he said.

    “Cultural prejudices about epilepsy result in patients and families being unwilling to seek help for the condition or to tell health workers about the symptoms. Many community health workers don’t have the training to recognize seizures, to educate the community about epilepsy, or to recommend appropriate treatment in most cases,” he said.

    “Finally, the availability of medicines at the community level is limited. Many of the standard epilepsy medicines are either not available at all or the availability is inconsistent. Reducing the treatment gap will require addressing all of these issues.”

    Stigma as a barrier to research: Life experiences of women with epilepsy in India

    In 2014, Jane von Gaudecker conducted an intensive study of six women in Kerala, India, highlighting the issues they face surrounding marriage, as well as other psychosocial and medical issues.

    Von Gaudecker, currently assistant professor at Indiana University School of Nursing, dressed traditionally while conducting the study and spoke the local language fluently. However, she still came to be known as the “epilepsy lady,” which was a major barrier to interviewing women. Of the 21 potential participants, 8 of them would not speak with her, in spite of assured confidentiality, for fear that the community would associate them with epilepsy. They were afraid of the effects on their daily lives, as well as marriage prospects.

    Six women did agree to extensive interviews; the findings are detailed in a publication, as well as an Epigraph article.

    ##

    ILAE is a global organization of health care professionals and scientists working toward a world where no person’s life is limited by epilepsy.

    Website | Facebook | Instagram

    Twitter feeds: English | French | Japanese | Portuguese | Spanish | ILAE-Young Epilepsy Section

    [ad_2]

    International League Against Epilepsy

    Source link

  • بحاث مايو كلينك تظهر أن ببتيلوفيماب خيار موثوق لعلاج كوفيد-19 في مرحلة السلالة BA.2، أحد المتحورات الفرعية الأخرى

    بحاث مايو كلينك تظهر أن ببتيلوفيماب خيار موثوق لعلاج كوفيد-19 في مرحلة السلالة BA.2، أحد المتحورات الفرعية الأخرى

    [ad_1]

    Newswise — مدينة روتشستر، ولاية مينيسوتا – يقول باحثو مايو كلينك إن الجسم المضاد أحادي النسيلة ببتيلوفيماب، المُرخص بالفعل من قبل إدارة الغذاء والدواء الأمريكية للاستخدام في حالات الطوارئ الخاصة بمتحور أوميكرون من فيروس كورونا المستجد (كوفيد-19)، هو خيار موثوق لعلاج سلالة BA.2 والمتحورات الفرعية الأخرى لفيروس كورونا المستجد (كوفيد-19). ونتائج دراستهم الاسترجاعية متعددة المواقع والتي شملت 3,607 مريضًا معرضين لمخاطر عالية، منشورة في مجلة الأمراض المعدية. 

    يقول رايموند رازونابل، دكتور الطب، أخصائي وباحث في الأمراض المعدية في مايو كلينك، والمؤلف الرئيسي للدراسة: “تمنحنا هذه الدراسة الثقة في أن ببتيلوفيماب يمكن الاعتماد عليه في علاج المرضى المعرضين لمخاطر عالية خلال حِقبة متحور أوميكرون هذه التي تتميز بمتحورات جديدة آخذة في الازدياد، وتعطينا أداة أخرى ضمن الجهود المبذولة لمكافحة فيروس كورونا المستجد (كوفيد-19)”. 

    لقد قارن الباحثون نتائج 2,833 مريضًا تم حقنهم بالجسم المضاد ببتيلوفيماب في غضون سبعة أيام من ظهور الأعراض الأولى، بمجموعة أخرى من 774 مريضًا وُصف لهم دواء نيرماتريلفير ريتونافير عن طريق الفم في غضون خمسة أيام من ظهور الأعراض. نظرًا لأن الجسم المضاد ببتيلوفيماب مُرخص للاستخدام في حالات الطوارئ، بناءً على بيانات سريرية محدودة، فقد حددت الإرشادات أن يتم استخدامه كعلاج بديل للمرضى المعرضين لمخاطر عالية والذين لا يستطيعون أخذ نيرماتريلفير ريتونافير أو اي في ريمسيفير. 

    وأظهرت نتائج الدراسة أن 1.4% فقط من المرضى الذين عولجوا بالجسم المضاد ببتيلوفيماب وصل بهم مآل المرض إلى مرض خطير في غضون 30 يومًا. ويقول الباحثون أن هذه النتائج مماثلة لنتائج أخرى خاصة بدواء نيرماتريلفير ريتونافير والذي كان بنسبة 1.2%، وعلاجات الأجسام المضادة أحادية النسيلة الأخرى المُرخصة مسبقًا والمُستخدمة قبل ظهور السلالة BA.2، حيث وصلت نسبة دخول وحدة العناية المركزة 0.4% مع استخدام الجسم المضاد ببتيلوفيماب، و0.2% مع استخدام الدواء نيرماتريلفير ريتونافير. 

    وكان من بين المرضى المعرضين لمخاطر عالية المصابين بمجموعة واسعة من الحالات المرضية، ولكن في هذه الفئة من السكان، كان الأكثر شيوعًا هو فرط ضغط الدم، وداء السكري، وبعض أشكال حالات تثبيط المناعة. كانت مجموعة الدراسة في الغالب من البيض، بمتوسط عمر يبلغ 66 عامًا. 

    يقول الباحثون إن هذه هي أول دراسة واقعية تقارن فعالية هذين الخيارين العلاجين لدى أعداد كبيرة من المرضى المصابين بفيروس كورونا المستجد (كوفيد-19) خلال موجة سلالة BA.2. وهي أكبر مجموعة من المرضى تُعالج بالجسم المضاد ببتيلوفيماب. تدعم النتائج استخدام ببتيلوفيماب كخيار مفيد للمرضى المعرضين لمخاطر عالية والذين لا يمكن علاجهم باستخدام دواء نيرماتريلفير ريتونافير عن طريق الفم. ويواصل المؤلفون تقييم فعاليته مع ظهور متحورات جديدة. 

    تم تمويل الدراسة من قبل مايو كلينك. المؤلف الرئيسي للدراسة هو جون أوهورو، دكتور الطب، أخصائي الأمراض المعدية في مايو كلينك. المؤلفون المشاركون هم سيندا تولدج-شيتل، دكتورة الطب؛ سارة إن. هانسون، دكتوراة في تقويم العظام؛ ريتشارد أرندت، دكتور صيدلة؛ لي سبايكر، دكتورة الطب؛ تيريزا سيفيلي، دكتورة الطب؛ جينيفر لارسن؛ ورافيندرا جانيش، دكتور الطب، وجميعهم من مايو كلينك. 

    ### 

    نبذة عن مايو كلينك 

    مايو كلينك هي مؤسسة غير ربحية تلتزم بالابتكار في الممارسات السريرية والتعليم والبحث وتوفير التعاطف والخبرة لكل مَن يحتاج إلى الاستشفاء والرد على استفساراته. لمعرفة المزيد من أخبار مايو كلينك، تفضَّل بزيارة شبكة مايو كلينك الإخبارية 

     

    [ad_2]

    Mayo Clinic

    Source link

  • Novozymes and Chr. Hansen agree deal to merge

    Novozymes and Chr. Hansen agree deal to merge

    [ad_1]

    Danish biotechnology companies Novozymes AS
    NZYM.B,
    -10.74%

    and Chr. Hansen Holding AS
    CHR,
    +25.98%

    said Monday they have agreed to merge, creating a biological solutions provider with combined annual revenue of around 3.5 billion euros ($3.69 billion).

    The companies, which produce products such as enzymes, probiotics and biopharmaceutical ingredients, said the combination between two strategically complementary businesses will drive efficiencies while unlocking potential within biosolutions and providing additional growth opportunities.

    “Novozymes and Chr. Hansen share the strong conviction that our combined scale, know-how, commercial strengths, and innovation excellence will drive value for our shareholders, customers and society at large,” said Novozymes Chief Executive Ester Baiget.

    The deal will see Chr. Hansen shareholders receive 1.5326 new B-shares in Novozymes for each Chr. Hansen share, reflecting an implied premium of 49% to Chr. Hansen’s closing share price on Friday and valuing each Chr. Hansen share at 660.55 Danish kroner ($93.53) a share.

    Novo Holdings AS, the largest shareholder in both Novozymes and Chr. Hansen, will support the proposed merger and exchange its 22% stake in Chr. Hansen at an exchange ratio of 1.0227 new B-shares in Novozymes.

    The companies said they see annual revenue synergies of EUR200 million within four years after completion of the deal.

    Write to Dominic Chopping at dominic.chopping@wsj.com

    [ad_2]

    Source link

  • WSJ News Exclusive | Amgen in Advanced Talks to Buy Horizon Therapeutics

    WSJ News Exclusive | Amgen in Advanced Talks to Buy Horizon Therapeutics

    [ad_1]

    U.S. biotechnology company was the last of three suitors standing in an auction for Horizon

    [ad_2]
    Source link

  • Experimental Cancer Therapy Shows Success in More Than 70 Percent of Patients in Global Clinical Trials

    Experimental Cancer Therapy Shows Success in More Than 70 Percent of Patients in Global Clinical Trials

    [ad_1]

    Newswise — New York, NY (December 10, 2022) — A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

    The therapy, known as a bispecific antibody, binds to both T cells and multiple myeloma cells and directs the T cells—white blood cells that can be enlisted to fight off diseases—to kill multiple myeloma cells. The researchers described this strategy as “bringing your army right to the enemy.”

    The success of the off-the-shelf immunotherapy, called talquetamab, was even seen in patients whose cancer was resistant to all approved multiple myeloma therapies. It uses a different target than other approved therapies: a receptor expressed on the surface of cancer cells known as GPRC5D.

    Talquetamab was tested in phase 1 and phase 2 trials. The phase 1 trial, which was reported in The New England Journal of Medicine (NEJM), established two recommended doses that were tested in the Phase 2 trial. The results of the Phase 2 trial were reported at the American Society of Hematology annual meeting on Saturday, December 10. The study participants had all been previously treated with at least three different therapies without achieving lasting remission, suggesting talquetamab could offer new hope for patients with hard-to-treat multiple myeloma.

     “This means that almost three-quarters of these patients are looking at a new lease on life,” said Ajai Chari, MD, Director of Clinical Research in the Multiple Myeloma Program at The Tisch Cancer Institute and lead author of both studies. “Talquetamab induced a substantial response among patients with heavily pretreated, relapsed, or refractory multiple myeloma, the second-most-common blood cancer. It is the first bispecific agent targeting the protein GPRC5d in multiple myeloma patients.”

    Nearly all patients with myeloma who receive standard therapies continually relapse. Patients who relapse or become resistant to all approved multiple myeloma therapies have a poor prognosis, so additional treatments are urgently needed. This study, while an early-phase trial designed to detect tolerability and find a safe dose, is an important step in meeting that need.

    This Phase 1 clinical trial enrolled 232 patients at several cancer centers across the world between January 2018 and November 2021. Patients received a variety of doses of the therapy either intravenously or injected under their skin; future studies will focus on doses only administered under the skin either weekly or every other week

    The efficacy and safety findings in the phase 1 study were validated in the phase 2 trial presented at ASH. The phase 2 trial included 143 patients treated on a weekly dose and 145 patients treated at a higher biweekly dose.

    The overall response rate in these two groups was about 73 percent, Dr. Chari said. The response rate was maintained throughout various subgroups examined, with the exception of patients with a rare form of multiple myeloma that also extends to organs and soft tissues. More than 30 percent of patients in both groups had a complete response (no detection of myeloma-specific markers) or better, and nearly 60 percent had a “very good partial response” or better (indicating the cancer was substantially reduced but not necessarily down to zero).

    The median time to a measurable response was approximately 1.2 months in both dosing groups and the median duration of response to date is 9.3 months with weekly dosing. Researchers are continuing to collect data on the duration of response in the group receiving 0.8 mg/kg every other week and for patients in both dosing groups who had a complete response or better.

    Side effects were relatively frequent, but typically mild. About three-quarters of patients experienced cytokine release syndrome, which is a constellation of symptoms including fever that is common with immunotherapies. About 60 percent experienced skin-related side effects such as rash, about half reported taste changes, and about half reported nail disorders. The researchers said very few patients (5 to 6 percent) stopped talquetamab treatment because of side effects.

    The response rate observed in the study, which Dr. Chari explained is higher than that for most currently accessible therapies, suggests talquetamab could offer a viable option for patients whose myeloma has stopped responding to most available therapies, offering a chance to extend life and benefit from other new and future therapies as they are developed.

    These trials were sponsored and funded by Janssen.

      

    About the Mount Sinai Health System

    Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

    Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report‘s Best Hospitals, receiving high “Honor Roll” status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children’s Hospital among the country’s best in several pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report‘s “Best Medical Schools,” aligned with a U.S. News & World Report “Honor Roll” Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.

    For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.

    [ad_2]

    Mount Sinai Health System

    Source link

  • Michigan Medicine receives $50M; will name new hospital after philanthropists D. Dan and Betty Kahn

    Michigan Medicine receives $50M; will name new hospital after philanthropists D. Dan and Betty Kahn

    [ad_1]

    Newswise — ANN ARBOR, Mich. – Celebrating one of the largest gifts ever to Michigan Medicine of $50 million, the health system will name its new hospital for longtime philanthropists D. Dan and Betty Kahn.

    On Dec. 8, the University of Michigan Board of Regents approved a new name for University of Michigan Health’s 264-bed, 690,000-square-foot hospital — The D. Dan and Betty Kahn Health Care Pavilion — to honor Betty and Dan’s dedication to the University of Michigan and the public good.

    “Patients and families who come to Michigan Medicine see their lives changed,” said U-M President Santa J. Ono. “We are deeply grateful to the D. Dan and Betty Kahn Foundation for its extraordinary generosity, which will enable us to further develop and advance the highly specialized care, innovative research and comprehensive medical training that make our health system so exceptional.”

    The D. Dan and Betty Kahn Health Care Pavilion is scheduled to open in fall 2025. The $920 million facility will include 264 private inpatient rooms capable of converting into intensive care, a top-notch neurosciences center, and specialty services for cardiovascular and thoracic care. It will also feature 20 surgical and three interventional radiology suites.

    “This hospital is so important to the legacy of Betty and Dan Kahn and their focus on improving lives through advancements in health and science,” said Larry Wolfe, president and trustee of the D. Dan and Betty Kahn Foundation and son-in-law of the Kahns.

    “This gift is aligned perfectly with the Kahns’ vision and dedication to improving lives. This transformational gift will enhance the ability of Michigan Medicine to provide increased services to the people of the state of Michigan, as well as a wide cross section of our country,” Wolfe said. “The pandemic amplified the need for increased high-quality medical care, training, research and innovation — this is exactly what Michigan Medicine will do. To give to the University of Michigan is based on the trust and confidence that we at the Foundation have in the university and its leadership. The Kahn Foundation is proud to make this impactful gift based on need, proper stewardship and management.”

    The new hospital will allow for the relocation of beds currently in semi-private rooms at University Hospital, improving patient safety and experience while offering more space for family members. When all is complete, a total of 154 new beds will be added to the medical campus in Ann Arbor.

    “The generosity of the D. Dan and Betty Kahn Foundation will allow Michigan Medicine to provide essential increased access for patients to receive the highest quality medical care from our world-class providers,” said Marschall Runge, M.D., Ph.D., CEO of Michigan Medicine, dean of the U-M Medical School and executive vice president of medical affairs for the University of Michigan.

    “By relieving high capacity at University Hospital and having more ICU-capable beds, the facility will improve the patient experience for so many,” Runge said. “This will be yet another distinction that strengthens our academic medical center.”

    The D. Dan and Betty Kahn Foundation has a near-20-year history of transformational giving to the University of Michigan.

    In 2011, Dan Kahn created the Kahn Symposium, a collaboration between U-M and the Technion – Israel Institute of Technology. In 2018, the foundation established and expanded the Michigan-Israel Partnership for Research and Education, an alliance among U-M, Technion and the Weizmann Institute of Science that was envisioned by Dan Kahn and facilitates collaboration in medicine, science and engineering among these institutions.  

    The foundation also has supported cardiovascular research and care at Michigan Medicine, with gifts in 2009 and 2004, the latter made by Dan in memory of his beloved wife, Betty. The auditorium at U-M’s A. Alfred Taubman Biomedical Science Research Building and the Patient and Family Reception Area at the Frankel Cardiovascular Center are named in the Kahns’ honor.

    “My parents placed immense value on the power of education and continual learning,” said Patti Aaron, daughter of Dan and Betty Kahn, and vice president and trustee of the Kahn Foundation. “My father was especially inspired by scientific discovery and the possibilities for humankind, and he encouraged the same in his children and grandchildren. My parents’ philanthropy, in part, reflected those interests through support for world-class health science research institutions, such as Michigan Medicine.”

    The new hospital is being constructed adjacent to the Frankel Cardiovascular Center, and the two are set to be linked with bridge and tunnel connections. The facility is designed for sustainability to meet LEED (Leadership in Energy and Environmental Design) Platinum Building Certification, the highest possible rating.

    “With the Pavilion, Michigan will have one of the most state-of-the-art hospitals in the country — that also demonstrates environmental and social responsibility,” said David Miller, M.D., president of U-M Health. “The D. Dan and Betty Kahn Health Care Pavilion will be a game changer for Michigan and our patients, as well as the faculty, staff and learners who are committed to caring for them.”

    “Michigan Medicine is all about people — their faculty and staff are outstanding, and the care is patient-centered,” said Arthur Weiss, secretary/treasurer and trustee of the Kahn Foundation. “This gift will ensure that they have the tools to continue the transformative work they do here and assist in the retention of high-quality medical professionals at Michigan Medicine. Having had the privilege to represent Betty and Dan, this gift falls perfectly in line with their legacy.”

    About the Pavilion:  

    The D. Dan and Betty Kahn Health Care Pavilion is a 12-floor, 264-bed inpatient facility being built on the University of Michigan Health, Michigan Medicine, medical campus in Ann Arbor. The $920 million, 690,000-square-foot hospital was approved for construction by University of Michigan Board of Regents in September 2019.

    Work on the project was paused due to the COVID-19 pandemic in 2020 but resumed in spring 2021. Construction crews will work to enclose the building’s exterior in winter 2023, and the hospital is scheduled to open fall 2025.

    About Michigan Medicine:

    At Michigan Medicine, we advance health to serve Michigan and the world. We pursue excellence every day in our five hospitals, 125 clinics and home care operations that handle more than 2.3 million outpatient visits a year, as well as educate the next generation of physicians, health professionals and scientists in our U-M Medical School.

    Michigan Medicine includes the top ranked U-M Medical School and University of Michigan Health, which includes the C.S. Mott Children’s Hospital, Von Voigtlander Women’s Hospital, University Hospital, the Frankel Cardiovascular Center, Kellogg Eye Center, University of Michigan Health West and the Rogel Cancer Center. The U-M Medical School is one of the nation’s biomedical research powerhouses, with total research funding of more than $500 million.

     

    More information is available at www.med.umich.edu 

    [ad_2]

    Michigan Medicine – University of Michigan

    Source link

  • Black patients more likely to get emergency colorectal cancer surgery

    Black patients more likely to get emergency colorectal cancer surgery

    [ad_1]

    Newswise — In an analysis of data from hospitals across the state of Michigan, University of Michigan researchers found that Black, non-Hispanic patients were more likely to undergo emergency surgery for colorectal cancer than other races and ethnicities.

    Undergoing emergency surgery was associated with a higher rate of complications, including death. Out of close to 5,000 patients who underwent any type of surgery for colorectal cancer, 23% had emergency surgery — but those patients made up 63% of the deaths.

    Patients who underwent emergency surgery also received less complete evaluations and testing as part of their workup by surgeons and their medical teams.

    “Overall, these results suggest that racial and ethnic differences persist in presentation and management of colorectal cancer and that these differences likely contribute to disparities in postoperative outcomes among these groups,” said Ryan Howard, M.D., M.S., a general surgery resident at University of Michigan Health and the first author of the study.

    Howard and his research team used data from the Michigan Surgical Quality Collaborative, a statewide initiative funded by Blue Cross Blue Shield of Michigan that aims to improve the quality and cost of surgical care across the state. 

    Their goal was to identify opportunities to improve patient care earlier in the process of cancer diagnosis and treatment.

    “We can spend all day working on, say, reducing complications right after surgery,” Howard said. “But if we’re still not getting the right treatment to the right patient at the right time, then we’re not doing a good enough job.”

    “Colorectal cancer is universally screened for and develops fairly slowly. So if someone is plugged into the health care system, the chances are very high that we will detect it and they will get the appropriate evaluation and work-up,” he added. “The fact that we found patients who are not getting that suggests that there is an opportunity to improve the care we deliver to patients, even before they get to the surgical episode.”

    Howard points to patient navigators and targeted community outreach as proven strategies to help reduce disparities in cancer care and believes the state of Michigan, with its network of collaborative quality initiatives, is well positioned to incorporate these solutions into future projects.

    [ad_2]

    Michigan Medicine – University of Michigan

    Source link

  • This fund beats the S&P 500 by using just 75 of its components. Here’s how it works.

    This fund beats the S&P 500 by using just 75 of its components. Here’s how it works.

    [ad_1]

    What worked well during the years-long bull market through 2021 — a focus on growth, regardless of price — has ground to a halt this year. The rebirth of the value style of investing — and modest valuations overall — has taken hold.

    The approach taken by the Invesco S&P 500 GARP ETF has paid off through both bull and bear markets.

    Let’s begin with a 10-year chart comparing total returns with dividends reinvested for the Invesco S&P 500 GARP ETF
    SPGP,
    +0.67%

    and the SPDR S&P 500 ETF Trust
    SPY,
    +0.78%
    ,
    which tracks the benchmark S&P 500:


    FactSet

    So far this year, SPGP is down 12%, while SPY is down 16%. But the long-term chart shows significant and consistent outperformance for SPGP, even during the bull market.

    The S&P 500 GARP Index

    GARP stands for “growth at a reasonable price.” SPGP tracks the S&P 500 GARP Index, which is reconstituted and rebalanced twice a year, on the third Fridays of June and December. The next change occurs Dec. 16.

    S&P Dow Jones Indices assigns a growth score to each component of the S&P 500 by averaging the three-year compound annual growth rate (CAGR) for earnings and sales per share.

    The top 150 components of the S&P 500 by growth score are eligible for inclusion in the GARP index. Those 150 are ranked by “quality/value composite score,” which is the average of these three ratios:

    • Financial leverage — total debt to book value.

    • Return on equity — trailing 12 months’ earnings per share divided by book value per share.

    • Earnings-to-price — 12 months’ earnings per share divided by the share price.

    The top 75 of the 150 by QV rankings are then included in the GARP index and weighted by the growth score, with portfolio weightings ranging from 0.5% to 5%.

    There is a weighting limitation of 40% to any one of the 11 S&P sectors.

    Addressing concentration risk

    The benchmark S&P 500 Index
    SPX,
    +0.75%

    is weighted by market capitalization, which means it is more heavily concentrated than you might expect — success is rewarded, with rising stocks more heavily weighted over time.

    That can backfire during a bear market, with Amazon.com Inc.
    AMZN,
    +2.14%

    down 47% and Tesla Inc.
    TSLA,
    -0.34%

    down 51% this year, to name two prominent examples.

    Looking at the SPDR S&P 500 ETF Trust
    SPY,
    +0.78%
    ,
    which is the first and largest exchange traded fund and tracks the benchmark index by holding all of its components, six companies (Apple Inc.
    AAPL,
    +1.21%
    ,
    Microsoft Corp.
    MSFT,
    +1.24%
    ,
    Amazon, both common share classes of Alphabet Inc.
    GOOGL,
    -1.30%

     
    GOOG,
    -1.26%

    and Berkshire Hathaway Inc.
    BRK.B,
    +0.06%

    ) make up 19.2% of the portfolio.

    That percentage has come down this year, but a lot of risk remains concentrated in a handful of companies. (Apple alone makes up 6.4% of the SPY portfolio. Tesla is now the ninth-largest holding, making up 1.4% of the portfolio.)

    One way to address high concentration in an index fund is to use an equal-weighted approach, which Mark Hulbert recently discussed.

    For the Invesco S&P 500 GARP ETF, the underlying index’s selection methodology has resulted in much less portfolio concentration than we see in SPY, with the top five holdings making up 10.9% of the portfolio.

    Here are the 10 largest holdings of SPGP:

    Company

    Ticker

    Share of portfolio

    Regeneron Pharmaceuticals, Inc.

    REGN,
    +0.15%
    2.49%

    Cigna Corporation

    CI,
    +0.39%
    2.26%

    Everest Re Group, Ltd.

    RE,
    +0.24%
    2.21%

    Vertex Pharmaceuticals Incorporated

    VRTX,
    +1.18%
    1.98%

    D.R. Horton, Inc.

    DHI,
    -0.39%
    1.97%

    Expeditors International of Washington, Inc.

    EXPD,
    +0.23%
    1.96%

    Incyte Corporation

    INCY,
    +0.10%
    1.92%

    Goldman Sachs Group, Inc.

    GS,
    -0.51%
    1.83%

    Ebay Inc.

    EBAY,
    +1.67%
    1.81%

    Pfizer Inc.

    PFE,
    +3.07%
    1.73%

    Source: FactSet

    Click on the tickers for more information about any company, ETF or index in this article.

    You should also read Tomi Kilgore’s detailed guide to the wealth of information for free on the MarketWatch quote page.

    Don’t miss: 10 Dividend Aristocrat stocks expected by analysts to rise up to 54% in 2023

    [ad_2]

    Source link

  • Estudo estabelece bases para prever a resposta antidepressiva em pessoas que tentaram suicídio

    Estudo estabelece bases para prever a resposta antidepressiva em pessoas que tentaram suicídio

    [ad_1]

    Newswise — ROCHESTER, Minnesota –Pesquisadores da Mayo Clinic descobriram que pessoas com transtorno depressivo maior e histórico de tentativa de suicídio possuem biomarcadores distintos que estão correlacionados com a resposta à terapia antidepressiva. As novas descobertas, publicadas na revista Frontiers Pharmacology, são a chave para estratégias de tratamento individualizado e identificação precoce dos pacientes com alto risco de suicídio.   

    Para o estudo, os pesquisadores usaram tecnologias multiômicas, (especialmente metabolômica e genômica) para analisar amostras de 350 pacientes com transtorno depressivo maior. Eles compararam as amostras dos pacientes com e sem histórico de tentativa(s) de suicídio e descobriram assinaturas multiômicas baseadas em sangue entre os dois grupos, apesar de todos os pacientes terem o mesmo diagnóstico de transtorno depressivo maior.   

    De acordo com a Organização Mundial da Saúde, aproximadamente 700 mil pessoas em todo o mundo morrem em decorrência de suicídio a cada ano, juntamente com tentativas não fatais de 10 a 20 vezes esse número. Uma tentativa anterior de suicídio é o maior fator de risco para suicídio na população em geral.  

    “Avaliar os pacientes suicidas pode ser desafiador, pois as avaliações de risco clínico são inerentemente subjetivas e o transtorno depressivo maior tem altos graus de variabilidade”, afirma Dr. Paul Croarkin, osteopata e mestre em Ciências, psiquiatra no departamento de psiquiatria e psicologia na Mayo Clinic e investigador sênior do estudo. “Nosso estudo estabelece bases para o avanço do potencial prognóstico dessa doença e melhorar os resultados dos pacientes que usam biomarcadores biológicos e digitais.” 

    A equipe descobriu que as variações nos genes CLOCK e ARNTL são diferentes nos pacientes com e sem tentativa anterior de suicídio. Ambos os genes estão relacionados com o ritmo circadiano, que regula as funções críticas do corpo, inclusive comportamento, metabolismo, níveis de hormônio e sono. Essas variações genéticas específicas também estão associadas a menores taxas de resposta e remissão antidepressiva.  

    A metabolômica é o estudo dos metabolitos, que são substâncias criadas quando o corpo metaboliza alimentos, drogas ou o próprio tecido. A genômica é o estudo dos genes, que influenciam as enzimas fundamentais para a metabolização dos medicamentos. Ainda que elas possam explicar individualmente os aspectos dos processos biológicos, analisá-las conjuntamente tem o potencial de revelar as interações que não foram estudadas previamente.   

    De modo geral, a multiômica é uma combinação de duas ou mais abordagens “ômicas”. Exemplos adicionais multiômicos incluem a proteômica (o estudo das proteínas), a epigenômica (o estudo das mudanças epigenéticas no DNA) e a transcriptômica (o estudo das moléculas de RNA).   

    Ao avaliar simultaneamente o genoma e o metaboloma, os pesquisadores descobriram assinaturas biológicas que não poderiam ser encontradas pelo genoma ou metaboloma sozinho.  

    O estudo faz parte dos esforços contínuos na Mayo Clinic para entender a biologia das tendências ao suicídio para melhorar as abordagens diagnósticas, os tratamentos e os resultados para pacientes com depressão e outros transtornos de humor.  

     

    ###        

    Sobre a Mayo Clinic    A Mayo Clinicé uma organização sem fins lucrativos comprometida com a inovação na prática clínica, educação e pesquisa, fornecendo compaixão, conhecimento e respostas para todos que precisam de cura. Visite a Rede de Notícias da Mayo Clinic para obter outras notícias da Mayo Clinic.  

       

    [ad_2]

    Mayo Clinic

    Source link

  • Ex-Theranos exec ‘Sunny’ Balwani sentenced to nearly 13 years in prison

    Ex-Theranos exec ‘Sunny’ Balwani sentenced to nearly 13 years in prison

    [ad_1]

    SAN JOSE, Calif. — A judge on Wednesday sentenced former Theranos executive Ramesh “Sunny” Balwani to nearly 13 years in prison for his role in the company’s blood-testing hoax — a sentence slightly longer than that given to the CEO, who was his lover and accomplice in one of Silicon Valley’s biggest scandals.

    Balwani was convicted in July of fraud and conspiracy connected to the company’s bogus medical technology that duped investors and endangered patients. His sentencing came less than three weeks after Elizabeth Holmes, the company’s founder and CEO, received more than 11 years in prison for her part in the scheme.

    The scandal revolved around the company’s false claims to have developed a device that could scan for hundreds of diseases and other potential problems with just a few drops of blood taken with a finger prick.

    The case threw a bright light on Silicon Valley’s dark side, exposing how its culture of hype and boundless ambition could veer into lies.

    Holmes, 38, could have gotten up to 20 years in prison — a penalty that U.S. District Judge Edward Davila could have imposed on Balwani, who spent six years as Theranos’ chief operating officer while remaining romantically involved with Holmes until a bitter split in 2016.

    While on the witness stand in her trial, Holmes accused Balwani, 57, of manipulating her through years of emotional and sexual abuse. Balwani’s attorney has denied the allegations.

    The two trials had somewhat different outcomes. Unlike Balwani, Holmes was acquitted on several charges of defrauding and conspiring against people who paid for Theranos blood tests that produced misleading results and could have pointed patients toward the wrong treatment. The jury in Holmes’ trial also deadlocked on three charges.

    Balwani was convicted on all 12 felony counts, and his lawyers sought a far more lenient sentence of just four to 10 months in prison. Prosecutors for the Justice Department asked for 15 years. A probation report recommended nine years.

    Duncan Levin, a former federal prosecutor who is now a defense attorney, described Balwani’s bid for a light sentence as “utterly unrealistic.” Levin suspects the judge may give greater weight to the Justice Department and the probation office recommendations, which mirror the sentences those agencies sought for Holmes.

    The judge ultimately gave her 11 1/4 years in prison and recommended that the sentence be served in a low-security facility in Byran, Texas.

    Federal prosecutors also want the judge to order Balwani to pay $804 million in restitution to defrauded investors — the same amount sought from Holmes. Davila deferred a decision on restitution during Holmes’ Nov. 18 sentencing until an unspecified future date.

    In court documents, Balwani’s lawyers painted him as a hardworking immigrant who moved from India to the U.S. during the 1980s to become the first member of his family to attend college. He graduated from the University of Texas in 1990 with a degree in information systems.

    He later moved to Silicon Valley, where he first worked as a computer programmer for Microsoft before founding an online startup that he sold for millions of dollars during the dot-com boom of the 1990s.

    Balwani and Holmes met around the same time she dropped out of Stanford University to start Theranos in 2003. He became enthralled with her and her quest to revolutionize health care.

    Balwani’s lawyers said he eventually invested about $5 million in a stake in Theranos that eventually became worth about $500 million on paper — a fraction of Holmes’ one-time fortune of of $4.5 billion.

    That wealth evaporated after Theranos began to unravel in 2015 amid revelations that its blood-testing technology never worked as Holmes had boasted in glowing magazine articles that likened her to Silicon Valley visionaries such as Apple co-founder Steve Jobs.

    Before Theranos’ downfall, Holmes teamed up with Balwani to raise nearly $1 billion from deep-pocketed investors that included software mogul Larry Ellison and media magnate Rupert Murdoch.

    “Mr. Balwani is not the same as Elizabeth Holmes,” his lawyers wrote in a memo to the judge. “”He actually invested millions of dollars of his own money; he never sought fame or recognition; and he has a long history of quietly giving to those less fortunate.” Balwani’s lawyers also asserted that Holmes “was dramatically more culpable” for the Theranos fraud.

    Echoing similar claims made by Holmes’s lawyers before her sentencing, Balwani’s attorneys also argued that he has been adequately punished by the intense media coverage of Theranos, which has been the subject of a book, documentary and award-winning TV series.

    Balwani “has lost his career, his reputation and his ability to meaningfully work again,” his lawyers wrote.

    Federal prosecutors cast Balwani as a ruthless, power-hungry accomplice in crimes that ripped off investors and imperiled people who received flawed results. The blood tests were to be available in a partnership with Walgreen’s that Balwani helped engineer.

    “Balwani presented a fake story about Theranos’ technology and financial stability day after day in meeting after meeting,” the prosecutors wrote in their memo to the judge. “Balwani maintained this façade of accomplishments, after making the calculated decision that honesty would destroy Theranos.”

    [ad_2]

    Source link

  • Ground-breaking new method for multi-cancer early detection

    Ground-breaking new method for multi-cancer early detection

    [ad_1]

    Newswise — When cancer is detected at an early stage, the rates of survival increase drastically, but today only a few cancer types are screened for. An international study led by researchers from Chalmers University of Technology, Sweden, shows that a new, previously untested method can easily find multiple types of newly formed cancers at the same time – including cancer types that are difficult to detect with comparable methods.

    Cancer is one of the deadliest diseases in the world and is more difficult to cure when detected at a late stage.

    Finding effective methods for early detection of several types of cancer at the same time, so-called Multi-Cancer Early Detection (MCED), is an emerging research area. Today’s established screening tests are cancer type-specific, which means that patients need to be tested for each cancer type separately. Emerging MCED tests under development are usually based on genetics, for example measuring DNA fragments from tumours circulating in the blood. But DNA-based methods can only detect some types of cancer and have limited ability to find tumours at the earliest stage, so called stage I.

    New method based on human metabolism
    Now, in an international collaboration, researchers from Chalmers have developed a new method for multi-cancer early detection that is instead based on human metabolism. The results, which have been published in the scientific journal PNAS, uncover new opportunities for cheaper and more effective cancer screening. In a study totalling 1 260 participants, the researchers first discovered that the new method could detect all 14 cancer types that were tested. Next, they showed that twice as many stage I cancers in asymptomatic healthy people can be detected with the new method compared to the emerging DNA-based MCED tests.

    “This is a previously unexplored method, and thanks to the fact that we have been able to test it in a large population, we can show that it is effective in finding more stage I cancers and more cancer types. The method makes it possible to find cancer types that are not screened for today and cannot be found with DNA-based MCED tests, such as brain tumours and kidney cancer,” says Francesco Gatto, who is a visiting researcher at the Department of Biology and Biological Engineering at Chalmers and one of the study’s authors.

    Cheaper and more practical tests
    The method is based on a discovery by Dr. Francesco Gatto and Prof. Jens Nielsen at Chalmers almost ten years ago: that so-called glycosaminoglycans – a type of sugar that is an important part of our metabolism – are excellent biomarkers to detect cancer noninvasively. The researchers developed a machine learning method in which algorithms are used to find cancer-indicating changes in the glycosaminoglycans. The method uses comparatively small volumes of blood or urine, which makes them more practical and cheaper to use.

    “The fact that the method is comparatively simple means that the cost will be significantly low, ultimately enabling more people to have access to and take the test,” says Francesco Gatto.

    Important step towards effective multi-cancer tests
    In the next step, the researchers hope to be able to conduct a study with even more participants to further develop and confirm the method’s potential for screening use.

    “This is a ground-breaking study that gives us hope that one day society will be able to create screening programmes that can detect all cancer types early,” says Francesco Gatto.

    “To be able to find more cancer cases early, we know that new tools are needed. These results are very promising because of the demonstrated higher sensitivity across more types of cancer at stage I, using a cost-efficient and accessible technology,” says Dr. Eric Jonasch, MD, Professor at The University of Texas MD Anderson Cancer Center and co-author of the study.

    The article “Non-invasive multi-cancer early detection using glycosaminoglycans” has been published in the scientific journal Proceedings of the National Academy of Sciences (PNAS).

    • The study has been led by researchers from Chalmers in collaboration with over 30 partners at 10 different universities and research institutes in Sweden and internationally. These are:  Lund University, Sweden, Uppsala University, Sweden, Sahlgrenska Academy at University of Gothenburg, Sweden, Karolinska Institute, Sweden, Vancouver Prostate Centre, Canada, University of British Columbia, Canada, Università Vita-Salute San Raffaele, Italy, University of Modena and Reggio Emilia, Italy, University of Texas MD Anderson Cancer Center, USA, and University of Copenhagen, Denmark.
    • The method has already taken the step into society through the start-up company Elypta, which is one of Chalmers Ventures’ portfolio companies. Elypta is based on the research presented in the scientific study and focus on developing and commercialising MCED tests as well as a test for recurrent kidney cancer. In addition, Elypta has developed the measurement methods used to support the study analysis.

    More about the research
    The study shows that a method based on analysing changes in glycosaminoglycans – a type of sugar that is an important part of our metabolism – can be used to detect several different cancer types at an early stage from the same blood and urine sample, even cancer types that are difficult to detect with other methods.  The researchers chose to test 14 different cancer types, representing the majority of newly diagnosed cancers, and all 14 types could be detected with the new method. 1 260 people participated in the study, both healthy and previously diagnosed with cancer.  With this new method of multi-cancer early detection (MCED), twice as many cases of cancer at its earliest stage (stage I) in otherwise asymptomatic healthy people could be detected compared to other DNA-based MCED tests under development.

    [ad_2]

    Chalmers University of Technology

    Source link

  • After Years of Ankle Pain and Limited Mobility, Life-Changing Surgery at HSS

    After Years of Ankle Pain and Limited Mobility, Life-Changing Surgery at HSS

    [ad_1]

    Newswise — After years of searching for answers and numerous doctor consultations, 59-year-old Kathleen Kaler finally found relief from the severe ankle pain and instability that had plagued her for years. At Hospital for Special Surgery (HSS), Constantine Demetracopoulos, MD, performed successful ankle replacement surgery.

    Kaler, who is from Long Island, says the surgery changed her life. She can now engage in activities most people take for granted – walking normally without pain, wearing shoes she likes, being able to do her job, working in her backyard.

    “You have no idea how grateful I am. Before the surgery, my left ankle was collapsing, it could barely support my weight,” says Kaler, a slim 5 foot 7. “All my shoes were worn out on one side.” Her ankle was so unstable, she lived in fear that she would fall or break it, despite the rigid plastic brace she wore from her foot to her knee, day in and day out. She could only wear one type of shoe that she needed to replace every three months.

    As a child, Kaler recalls constantly twisting her ankle. Her parents took her to several doctors, and she was given a shoe insert to help with her high foot arches. Years later, arthritis set in, and the pain worsened and became more debilitating. Cortisone shots could only do so much, and she resumed the search for a long-lasting solution. Four doctors said nothing could be done. One orthopedic surgeon said the problem might be corrected with four separate surgeries, which she declined.

    Then she learned about total ankle replacement during an appointment with a doctor at HSS Long Island. It’s a complex surgery performed by relatively few orthopedic surgeons, and she was referred to Dr. Demetracopoulos, director of the HSS Total Ankle Replacement Center at the main hospital in Manhattan.

    “One of the few centers of its kind, we have a team of foot and ankle specialists, anesthesiologists, radiologists, nurses and physical therapists who have extensive experience in ankle replacement,” he explains. “We strive to provide the best possible care for each of our patients and have grown our volume to become one of the top institutions nationwide in ankle replacement.”

    Kaler says her consultation with Dr. Demetracopoulos gave her hope, and she would not be disappointed. She had the surgery in April 2021. “He saved my life. I never cry, but I cried in front of him, I was so grateful,” she says.

    “Ankle replacement is considered when patients are no longer able to manage arthritis pain with nonsurgical treatments such as physical therapy, appropriate footwear, an ankle brace or anti-inflammatory medication,” Dr. Demetracopoulos explains. “They have consistent pain that limits their activities and affects their quality of life.”

    Like other types of joint replacements, the surgery involves replacing the damaged bone and cartilage in the ankle with a prosthesis. The implant, made of metal and plastic, has the shape of a natural joint and seeks to provide normal, pain-free movement.

    The last 15 years have brought vast improvements in ankle replacement implants, technology and surgical techniques, making it a viable option for many patients suffering from severe arthritis, says Scott Ellis, MD, another orthopedic surgeon specializing in foot and ankle surgery at HSS.

    One of the most noteworthy advances in ankle replacement is patient-specific instrumentation, or PSI, Dr. Ellis says. It entails obtaining a CT scan of the patient’s ankle and developing a customized presurgical plan tailored to the individual’s anatomy. “PSI has been a game changer. It enables us to choose an implant that is the perfect size and map out a very precise surgery for optimal alignment and positioning,” he says.

    For people considering an ankle replacement, the first step is a thorough assessment of the ankle and the foot, and a discussion of patient goals and expectations. Imaging and other tests determine if a patient is a candidate. For someone whose ankle is very stiff with limited mobility or a severe deformity, a fusion of the ankle bones might be a better option and is also very successful in relieving pain, the HSS experts say. An ankle fusion would also be a better option for someone with weakened bones or osteoporosis. The benefit of ankle replacement over fusion is better movement after surgery.

    Sometimes an ankle replacement needs to be combined with another procedure, as it was in Kaler’s case. “Hers was a complex surgery. She had a type of foot that predisposed her to ankle instability,” Dr. Demetracopoulos explained. “In addition to treating her arthritis with the ankle replacement, we needed to treat the instability by repairing the ligaments in her ankle and by correcting the alignment in her foot, so it was in the right position.” 

    Kaler says she experienced no pain after surgery, which Dr. Demetracopoulos attributes to advances in nerve block anesthesia and pain management protocols after the procedure. He notes that each patient experiences pain differently, though.

    The HSS doctors expect 90 percent of ankle replacements to last 10 years. If the implant wears out, patients could be candidates for a revision ankle replacement or an ankle fusion. The physicians follow and monitor patients in a joint replacement registry at HSS. “One of our core missions at HSS is not only to deliver the care and do the best surgery we can for our patients, but to collect data over time that we can share with other surgeons and clinicians,” Dr. Demetracopoulos says.

    Kaler says the surgery has enabled her to regain her confidence. She can now drive her stick-shift Mini Cooper and carry out her demanding job responsibilities at a major home improvement store. “I’m all over the place, to the point where my friends and colleagues are saying, ‘slow down,'” she adds, making up for lost time and living life to the fullest.

    About HSS

    HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the 13th consecutive year), No. 3 in rheumatology by U.S. News & World Report (2022-2023), and the best pediatric orthopedic hospital in NY, NJ and CT by U.S. News & World Report “Best Children’s Hospitals” list (2022-2023). In a survey of medical professionals in more than 20 countries by Newsweek, HSS is ranked world #1 in orthopedics for a third consecutive year (2023). Founded in 1863, the Hospital has the lowest complication and readmission rates in the nation for orthopedics, and among the lowest infection rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center five consecutive times. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New JerseyConnecticut and in the Long Island and Westchester County regions of New York State, as well as in Florida. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Innovation Institute works to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, allied health professionals, academic trainees, and consumers in more than 145 countries. The institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. www.hss.edu.

    [ad_2]

    Hospital for Special Surgery

    Source link

  • Researchers Study Use of Virtual Reality to Lessen Pain, Anxiety During Vasectomy

    Researchers Study Use of Virtual Reality to Lessen Pain, Anxiety During Vasectomy

    [ad_1]

    Newswise — Researchers from the Desai Sethi Urology Institute, part of the University of Miami Miller School of Medicine, have launched a study to determine if wearing virtual reality headsets during in-office vasectomy helps relieve patients of procedure-related pain and anxiety.

    Miller School researchers have partnered for the study with the company Smileyscope, which has developed virtual reality hardware to meet or exceed health care standards. Company experts created the technology in this trial specifically as a virtual reality treatment for pain relief during office procedures performed using local anesthesia.

    “Studies suggest that virtual reality can safely decrease pain in children undergoing IV procedures. We think virtual reality might also play a role in distracting and comforting adult patients. Our hypothesis is that the technology could diminish the pain and anxiety that adult men associate with vasectomy and potentially many other in-office procedures,” said study investigator Ranjith Ramasamy, M.D., associate professor and director of the Miller School’s Reproductive Urology Program.

    “We are also comparing virtual with augmented reality to determine if a static scene, in this case a beach with music, helps more or less to diminish pain and anxiety than an interactive magic show.”

    One of the biggest concerns for men considering a vasectomy is pain or anxiety related to pain, said Akhil Muthigi, M.D., a study investigator and reproductive urology fellow working with Dr. Ramasamy.

    “A lot of patients want the vasectomy, but in the end the anxiety or fear is too high, and they don’t go through with it,” said Dr. Muthigi. “We will see if this technology helps to make the actual experience in the clinic a less painful experience, which would be a win for not only the patients but also the urologists doing these common procedures.”

    Studying Effects of Headsets

    During the next six months, researchers will recruit 150 to 180 men undergoing in-office vasectomy at the Desai Sethi Urology Institute. The men will be randomized into three groups: One group will wear virtual reality headsets with a static beach scene and music during the procedure; another group will wear 

    headsets that feature a magic show that they can interact with by eye movements; and the third group will undergo the traditional procedure with no additional technology.

    Researchers are using patient surveys to measure pain and anxiety scores before, during, and after the procedure, according to study investigator Farhan Qureshi, an M.D./Ph.D. student at the Miller School.

    “Another thing that’s novel about this study is that we’re using Fitbit wearable devices to measure physiological pain measures, including heart rate, skin temperature, and oxygenation levels before, during, and after the procedure,” Qureshi said.

    The study is timely, according to Dr. Ramasamy.

    “Demand for vasectomy procedures in the U.S. is trending up, especially with Roe vs. Wade being overturned,” Dr. Ramasamy said. “I was among the authors on a study recently published in the journal Cureus in which we found that internet searches for vasectomy jumped more than 120% following the leaked Supreme Court draft regarding Roe v. Wade.”

    For the study, Miller School researchers partnered with Smileyscope, an Australian-based company that developed the innovative and evidence-based virtual reality technology for use in health care.

    “During vasectomy, pain is generated at the procedure site, and the conventional approach is to control pain at that site. Importantly, we know pain is perceived in the brain. We are testing whether Smileyscope’s virtual reality can reduce pain by changing pain perception in the brain,” said Smileyscope’s Chief Medical Officer Paul Leong, M.B.B.S., Ph.D. “Using bespoke virtual reality during vasectomy has not been [studied in a clinical trial] before, and we are delighted to work with Dr. Ramasamy and colleagues.”

    The use of virtual reality could translate to many types of in-office procedures, according to Dr. Muthigi.

    “Vasectomy is one of the more common procedures we do in our clinic. But there are dozens of in-office procedures in the urology world that might benefit from the use of virtual reality; for example, prostate biopsies used to diagnose prostate cancer and cystoscopy to diagnose bladder cancer,” Dr. Muthigi said. “If the technology pans out in studies, clinicians might be using virtual reality to distract and calm patients having all types of in-office procedures in the future.”

    [ad_2]

    University of Miami Health System, Miller School of Medicine

    Source link

  • Care home nurses still need support to recover from Covid trauma, research shows

    Care home nurses still need support to recover from Covid trauma, research shows

    [ad_1]

    Newswise — Those on the front line of the Covid pandemic need mental health support to help them recover from, or manage, the stress and trauma they faced – according to University of East Anglia research.

    A new report published today investigates the impact of the pandemic on nurses working in care homes.

    It shows how care home nurses were unprepared for the situation they found themselves in, and that this impacted their mental health and wellbeing.

    The research team say that these frontline workers need a mental health and wellbeing strategy to help promote recovery from the symptoms of trauma and moral distress that they faced during the pandemic.

    Lead researcher Diane Bunn, from UEA’s School of Health Sciences, said: “Our work shows that care home nurses were completely unprepared for the extraordinary situation they found themselves in during the Covid-19 pandemic, and that this has impacted their mental health and wellbeing.

    “They had to manage a highly infectious new disease, associated with high mortality, in residents already living with complex clinical conditions.

    “They did this alongside staff shortages, constantly changing and conflicting guidelines and with minimal external professional support.

    “Health and social care staff are still very much in a recovery phase. They need time to recover from all that happened during the pandemic and many of them will need counselling and mental health support for some time.

    “Supporting care home nurses to recover from the pandemic is essential to maintain a healthy, stable workforce.”

    The research team carried out in-depth interviews with care home nurses about their experiences of the pandemic, across homes for older people in England and Scotland. They particularly focused on the nurses’ resilience and mental wellbeing.

    “All of the nurses we spoke to described being attentive to the needs of others, but less attentive to their own needs, which came at personal cost,” said Bunn.
     

    “There are many lessons to be learnt to support their recovery and ensure appropriate policies are in place in preparedness for the next pandemic,” she added.

    The study highlights a range of strategies to help nurses accept and recover from their experiences, and suggestions for how to better-prepare for future pandemics. These include:

    • Bespoke mental health and wellbeing strategy for care home nurses in the current pandemic recovery period and ensuring that this is ongoing and adaptable for future pandemics and disasters.
    • Wider professional and government recognition of the specialist skills required of care home nurses.
    • Revisit guidance to better prepare for any future pandemics and disasters on care homes
    • Involvement of care home nurses in the development of disaster-response policies in care homes.
    • Consistency of guidelines, and research-informed methods for effective communication of guidelines.

    “Support for care home nurses will likely benefit other care-home workers either directly through wider roll-out, or indirectly through improved wellbeing of nurse leaders,” added Bunn.

    This work was led by the University of East Anglia in collaboration with researchers at the University of Leicester. It was funded by the Burdett Trust for Nursing and the National Institute for Health and Care Research (NIHR).

    ‘Care-home Nurses’ responses to the COVID-19 pandemic: Managing ethical conundrums at personal cost: A qualitative study’ is published in the Journal of Nursing Scholarship on December 6, 2022.

    ENDS

    [ad_2]

    University of East Anglia

    Source link

  • Biobanco vivo de tecido mamário da Mayo Clinic desempenha papel importante em inovações de pesquisas

    Biobanco vivo de tecido mamário da Mayo Clinic desempenha papel importante em inovações de pesquisas

    [ad_1]

    Newswise — ROCHESTER, Minnesota — O biobanco vivo de tecido mamário da Mayo Clinic está ajudando pesquisadores a identificar as formas pelas quais as portadoras de determinados genes podem ter maior risco de câncer de mama. 

    Por exemplo, em um estudo recente, o biobanco mostrou a importância em entender a influência que o gene BRCA1 pode ter no aumento do risco de câncer de mama em mulheres portadoras de tal gene. A equipe da pesquisa usou amostras do biobanco para validar a descoberta, diz o Dr. Nagarajan Kannan, Ph.D., diretor do Laboratório de Biologia de Câncer e Células Tronco da Mayo Clinic. 

    Entender como o Biobanco Vivo de Tecido Mamário apoiou esse estudo significa entender a abrangência do seu propósito e o que o torna único. 

    “Em 2016, com o apoio de muitos colegas médicos e pesquisadores, eu fundei o biobanco para coletar tecidos de mulheres com uma mutação germinativa específica e que se submeteram a cirurgia de mama na Mayo Clinic Rochester”, diz o Dr. Kannan. 

    O biobanco agora coleta amostras em todos as instalações da Mayo Clinic e inclui qualquer gene associado ao aumento do risco de câncer de mama, ele acrescenta.  

    Na Mayo Clinic em Rochester, Minnesota, as amostras também incluem tecido mamário de cirurgias estéticas, incluindo tecido vivo mamário masculino.  

    “O acesso ao tecido vivo mamário masculino para estudar a origem do câncer de mama masculino tem sido um grande desafio, e nós resolvemos isso”, diz o Dr. Kannan. “Um em cada 100 casos de câncer de mama ocorre em homens, mas a glândula mamária masculina e o câncer de mama masculino ainda são pouco estudados. Nós queremos mudar isso usando o recurso único que desenvolvemos.” 

    As amostras de tecido mamário para o biobanco são coletadas no dia da cirurgia. Em seguida, elas são levadas para uma unidade central de processamento no laboratório do Dr. Kannan.  

    “O processo é bastante trabalhoso”, diz ele. “Cada amostra é coletada e processada prontamente, e leva mais de um dia e meio para gerar o que chamamos de ‘organoides de tecidos ricos em células-tronco epiteliais’. Essas são unidades de tecido que ainda possuem células-tronco autorrenováveis. Elas são criopreservadas e adicionadas ao banco. Há a possibilidade de danificar amostras durante as etapas de processamento devido a pequenos erros. Por isso, houve uma grande otimização da metodologia para simplificar esse processo.” 

    Muitos bolsistas de pesquisa, estagiários e tecnólogos contribuíram coletivamente com mais de 10.000 horas para coletar, processar e armazenar essas amostras ricas em células-tronco. 

    A especialidade de isolar o crescimento em células-tronco intactas é o motivo pelo qual o Dr. Kannan quis a palavra “vivo” no nome do biobanco. Mesmo os tecidos armazenados coletados em autópsias alguns dias após a morte geram células-tronco vivas. A morte da pessoas não extingue as células-tronco e células progenitoras do tecido mamário, e essas células são um recurso vital para a pesquisa. 

    Devido ao seu foco, o Biobanco Vivo de Tecido Mamário preenche uma lacuna específica de pesquisa.  

    “Estamos focados no tecido que não se tornou um tumor, porque queremos entender as vulnerabilidades celulares que aumentam o risco do câncer de mama”, diz o Dr. Kannan. “Nosso foco é entender os estágios iniciais do desenvolvimento do câncer de mama que normalmente não são apresentados na clínica”. 

    Atualmente, o biobanco conta com cerca de 500 amostras de pacientes. Cada amostra inclui uma pesquisa com cerca de 150 perguntas feitas aos participantes. A pesquisa fornece informações sobre outros fatores que podem contribuir para o risco elevado de câncer, como dieta, estilo de vida, genética e histórico familiar e médico. 

    Para obter mais informações, visite o site da Mayo Clinic Laboratories. 

    ###        

    Sobre a Mayo Clinic   A Mayo Clinicé uma organização sem fins lucrativos comprometida com a inovação na prática clínica, educação e pesquisa, fornecendo compaixão, conhecimento e respostas para todos que precisam de cura. Visite a Rede de Notícias da Mayo Clinicpara obter outras notícias da Mayo Clinic.   

    [ad_2]

    Mayo Clinic

    Source link

  • BioVie Shares jump Premarket on Parkinson’s, Alzheimer’s Studies >BIVI

    BioVie Shares jump Premarket on Parkinson’s, Alzheimer’s Studies >BIVI

    [ad_1]

    By Colin Kellaher

    Shares of BioVie Inc. rose sharply in premarket trading Tuesday after the clinical-stage biopharmaceutical company reported positive results from a pair of Phase 2 studies assessing the potential of its NE3107 drug candidate in Parkinson’s disease and Alzheimer’s disease.

    The Carson City, Nev., company said the study of NE3107 in Parkinson’s met both main objectives, with patients treated with a combination of the drug and levodopa seeing meaningful improvements in their motor score and an absence of adverse interactions of NE3107 with levodopa.

    BioVie said that based on the study findings, it will proceed with planning the Phase 3 program for discussion with the U.S. Food and Drug Administration.

    Meanwhile, BioVie said patients treated with NE3107 in the Alzheimer’s study experienced improved cognition and biomarker levels, with no drug-related adverse events observed.

    BioVie shares, which closed Monday at $5.21, were recently up 15% to $5.98 in premarket trading.

    Write to Colin Kellaher at colin.kellaher@wsj.com

    [ad_2]

    Source link

  • البنك الحيوي الحي للثدي في مايو كلينك يلعب دورًا رئيسيًا في إنجازات بحثية

    البنك الحيوي الحي للثدي في مايو كلينك يلعب دورًا رئيسيًا في إنجازات بحثية

    [ad_1]

    مدينة روتشستر، ولاية مينيسوتا. — يساعد البنك الحيوي الحي للثدي في مايو كلينك الباحثين في تحديد الطرق التي قد تزيد من احتمالية تعرض حاملي جينات معينة لخطر الإصابة بسرطان الثدي.

    [ad_2]

    Mayo Clinic

    Source link

  • Apple, Alibaba, NIO, and More Stock Market Movers Monday

    Apple, Alibaba, NIO, and More Stock Market Movers Monday

    [ad_1]

    Stock futures traded lower Monday as investors remained keyed on interest rate policy from the Federal Reserve and as a surge in China stocks over a loosening of Covid-19 restrictions in the country failed to boost U.S. equities.

    Here are some stocks that could make moves Monday:

    [ad_2]

    Source link

  • HSS Foot and Ankle Surgeon Spearheads Event to Provide New Shoes and Free Foot Exams to Homeless

    HSS Foot and Ankle Surgeon Spearheads Event to Provide New Shoes and Free Foot Exams to Homeless

    [ad_1]

    Newswise — Matthew Conti, MD, an orthopedic foot and ankle surgeon at Hospital for Special Surgery (HSS), and colleagues recently provided more than 100 pairs of new shoes and socks and offered free foot exams to homeless people at the Mainchance Drop-In Center in New York City. Dr. Conti, who recently joined HSS, launched the nonprofit Our Hearts to Your Soles when he was just 15 years old with his father, also a foot and ankle surgeon.

    The shoe giveaway in New York was one of 17 Our Hearts to Your Soles events in multiple states taking place in November and December. Orthopedic surgeons and other volunteers nationwide donate their services to provide much-needed footwear and exams to people who don’t have a place to call home. Along with Dr. Conti, his wife, three orthopedic surgeons in the HSS fellowship program and other hospital staff volunteered at the New York event on November 19.  

    Dr. Conti made it his mission to help when he was in high school. Volunteering at a wound care clinic in Pittsburgh, he saw the potentially devastating consequences when people with diabetes or another health condition develop severe wounds on their feet. He began to think about homeless people who develop foot problems because they don’t have a proper pair of shoes, especially during the cold weather months. A lack of access to medical care exacerbates the problem, potentially leading to foot infections, frostbite… or worse.

    In 2004, Dr. Conti teamed up with his father, Stephen Conti, MD, a foot and ankle surgeon in Pittsburgh, to launch Our Hearts to Your Soles to provide desperately needed footwear, socks and foot exams to homeless people. The organization has grown, and over the past 15 years has provided more than 50,000 pairs of shoes to people in need at annual events nationwide.

    For this year’s shoe-giveaway in New York, Dr. Conti partnered with Mainchance, which serves a diverse street homeless population of single adults. Center administrators identified and reached out in advance to clients who would benefit from new shoes, socks and foot exams, and 105 individuals showed up.

    Fortunately, nobody needed emergency foot care, but many desperately needed shoes. “The men and women we saw were very grateful. We saw multiple people who were jamming their feet into shoes that were 2 or 3 sizes too small,” Dr. Conti said. “One person absolutely lit up because he wore a size 15 shoe, but he said no one ever has his size.”

    For Kayla Collins, a patient care assistant at HSS who volunteered, the event hit close to home. “When I was younger, my mom had to move us into a shelter, so I personally understand what this event means to people who are less fortunate,” she explained. “It’s a humbling experience, and any opportunity I have to give back, I try to do so because you never know when you might find yourself in a similar situation.”

    Several orthopedic surgeons doing their fellowship training at HSS also helped out. “I’m fortunate to work at a teaching hospital where I mentor foot and ankle surgical fellows, as well as residents,” Dr. Conti explained. “This event provided them with a different patient care experience and allowed them to practice different skills, such as fitting people for shoes. As surgeons, we don’t do this every day, but in a short amount of time, we helped men and women feel more protected from the elements and avoid potential foot and ankle ailments.”

    This year, Red Wing Shoes generously donated 2,500 well-made, sturdy pairs of shoes for the nationwide events. The footwear is ideal for the many recipients who work outdoors. 

    Our Hearts to Your Soles only accepts donations of new footwear because, as Dr. Conti explains, “in addition to providing protection, a gift of brand-new shoes provides a tremendous boost to recipients’ self-esteem.”

    About HSS

    HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the 13th consecutive year), No. 3 in rheumatology by U.S. News & World Report (2022-2023), and the best pediatric orthopedic hospital in NY, NJ and CT by U.S. News & World Report “Best Children’s Hospitals” list (2022-2023). In a survey of medical professionals in more than 20 countries by Newsweek, HSS is ranked world #1 in orthopedics for a third consecutive year (2023). Founded in 1863, the Hospital has the lowest complication and readmission rates in the nation for orthopedics, and among the lowest infection rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center five consecutive times. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State, as well as in Florida. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Innovation Institute works to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, allied health professionals, academic trainees, and consumers in more than 145 countries. The institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. www.hss.edu.

    About Our Hearts to Your Soles

    The mission of Our Hearts to Your Soles is to provide the less fortunate across the United States with shoes and free foot examinations. The nonprofit believes that proper foot health is an essential part of everyday life and important to an overall health maintenance program. Over the past 15 years, the organization has provided more than 50,000 pairs of shoes to people in need at annual events nationwide.

    [ad_2]

    Hospital for Special Surgery

    Source link

  • UT Southwestern honored for health care leadership development

    UT Southwestern honored for health care leadership development

    [ad_1]

    Newswise — DALLAS – Dec. 02, 2022 – UT Southwestern Medical Center is one of seven health systems in the nation being recognized for its leadership development initiatives, the latest in a series of national and regional employer honors.

    The National Center for Healthcare Leadership (NCHL) honors a select number of health care systems nationwide for evidence-based leadership practices that drive quality care and improved outcomes with its Best Organizations for Leadership Development (BOLD) Award. The award recognizes strength in leadership development programming, diversity and inclusion, performance management, coaching programs, program monitoring, and recruitment.

    “This national recognition further demonstrates UT Southwestern’s commitment to developing the next generation of health care leaders, along with top scientists, physicians, and other providers in the health care field,” said Holly G. Crawford, Executive Vice President for Business Affairs at UT Southwestern. “As we do with our scientific, medical, and training missions, we apply data-driven strategies to nurture leaders who contribute to our institution’s culture of integrity, inclusiveness, and collaboration, and extend those qualities throughout the organization.”

    UT Southwestern, with an operating budget of over $4 billion and a workforce of nearly 23,000, earlier this year was named one of the 10 best large employers in the United States and among the top five health care employers in America’s Best Employers 2022 list compiled by Forbes and Statista. UTSW ranked No. 3 in the nation on Forbes’ list of America’s Best Employers for New Graduates, placing it in the top 1%, and highest among academic medical centers. UT Southwestern also ranked as the top health care employer for diversity in the U.S. and among the top 20 across all industries; and was the only health care institution listed among the top 20 employers nationally. UT Southwestern is among the top 40 institutions honored by Forbes as Best Employers for Women 2021 as well.

    UT Southwestern has developed a broad spectrum of programming that helps develop employees for future management and leadership roles, including technical skills to master new software and technologies, and successfully navigate stress and finances.

    Among its offerings are:

    • Leadership programs for new and recently promoted leaders
    • Core leadership training for all people-managers, as well as targeted programs for nurse leaders, administrators, and aspiring leaders
    • An M.B.A. program in collaboration with UT Dallas specifically targeted to the health care industry
    • Interactive programs to hone scientific leadership and management skills for junior faculty
    • A departmental diversity leaders group that shares ideas, expertise, and promotion of best practices to advance diversity, equity, and inclusion
    • Implicit bias training
    • Executive leadership training for senior women faculty members
    • Programs to develop success in obtaining research and community grants

    Staff training includes aspiring and emerging leaders programs, new leader onboarding, a Master of Science in Management program, online and app-based learning and leadership opportunities, and a multitude of business resource groups that foster inclusiveness and a sense of belonging at UT Southwestern.

    “As one of the nation’s leading academic medical centers, UT Southwestern has many top minds in a broad range of fields that help forge a pipeline of exceptionally trained, diverse talent who are prepared to create and initiate innovative solutions for the many challenges facing health care today,” said Jeremy Falke, Vice President and Chief Human Resources Officer at UT Southwestern.

    UT Southwestern’s William P. Clements Jr. University Hospital is the No. 1 ranked hospital in Dallas-Fort Worth – the nation’s fourth-largest metropolitan area – by U.S. News & World Report and is ranked among the top hospitals nationally in nine specialties. UTSW has been recognized among Hospital Careers’ Top 100 Best Hospitals to Work for, Best Places to Work for Postdocs by The Scientist, and holds Magnet Recognition from the American Nurses Credentialing Center.

    UT Southwestern is further recognized as a Top Veteran-Friendly Company by U.S. Veterans Magazine; as a top Mother-Friendly Worksite by the Texas Department of State Health Services; a Top Health Care Company in Best of the Best Awards for Hispanic Network Magazine and Black EOE Journal; and received the Lex Frieden Employment Award from the Texas Governor’s Committee on People with Disabilities,  Health Professions Higher Education Excellence in Diversity (HEED) Award from INSIGHT Into Diversity, and the Corporate Citizen Award from LaunchAbility.

    About UT Southwestern Medical Center

    UT Southwestern, one of the nation’s premier academic medical centers, integrates pioneering biomedical research with exceptional clinical care and education. The institution’s faculty has received six Nobel Prizes, and includes 24 members of the National Academy of Sciences, 18 members of the National Academy of Medicine, and 14 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,900 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide care in more than 80 specialties to more than 100,000 hospitalized patients, more than 360,000 emergency room cases, and oversee nearly 4 million outpatient visits a year.

    [ad_2]

    UT Southwestern Medical Center

    Source link